-
Company Profile
Avanir Pharmaceuticals Inc – Company Profile
Avanir Pharmaceuticals Inc (Avanir), a subsidiary of Otsuka Pharmaceutical Co Ltd. is a biopharmaceutical company that focuses on the research, development, and commercialization of medical and pharmaceutical treatments for central nervous system disorders. The company’s lead product include Nuedexta, a medication used for the treatment of pseudobulbar affect (PBA). The company's pipeline product include AVP-786 intended for the treatment of agitation in Alzheimer’s disease, residual schizophrenia, intermittent explosive disorder, disinhibition in dementia and traumatic brain injury behavioral dysfunction, among others....
Add to Basket -
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – (deudextromethorphan hydrobromide + quinidine sulfate)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry (deudextromethorphan hydrobromide + quinidine sulfate) Drug Details AVP-786 is under development for the treatment...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – (dextromethorphan + quinidine sulfate)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry (dextromethorphan + quinidine sulfate) Drug Details Dextromethorphan hydrobromide and quinidine sulfate (Neudexta) is a...
-
Product Insights
Migraine Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Migraine is a disorder characterized by repeated attacks of severe headache. A migraine headache causes throbbing or pulsating pain, usually on only one side of the head. These headaches are often associated with nausea, vomiting, and extreme sensitivity to light and sound. Symptoms include problems speaking, tingling in face, arms, and shoulders, pain behind one of the eyes and pain that gets worse with routine physical activity. The Migraine pipeline drugs market research report provides comprehensive information on the therapeutics...
-
Product Insights
Schizophrenia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The symptoms of Schizophrenia include delusions, hallucinations, disorganized speech, and disorganized behavior. Risk factors include family history, age, drugs (psychoactive), and weakened immune system. Treatment includes antipsychotic medications. The Schizophrenia pipeline market research report provides comprehensive information on the therapeutics under development for Schizophrenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Amyotrophic Lateral Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The symptoms of amyotrophic lateral sclerosis include difficulty breathing, difficulty swallowing, head drop due to weakness of the neck muscles, muscle cramps, speech problems, such as a slow or abnormal speech pattern (slurring of words), voice changes, hoarseness, weight loss. The Amyotrophic Lateral Sclerosis pipeline market research report provides comprehensive information on the therapeutics under development for Amyotrophic Lateral Sclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type....
-
Product Insights
Depression Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Its signs and symptoms include sleep disturbances, including insomnia or sleeping too much, appetite changes, anxiety, agitation, or restlessness, and physical problems like back pain or headaches. Depression can be treated via antidepressants, mood stabilizers, or antipsychotics. The Depression pipeline market research report provides comprehensive information on the therapeutics under development for Depression, complete with analysis by stage of development, drug target, mechanism of...
-
Product Insights
Traumatic Brain Injury Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Traumatic brain injury happens when an external mechanical force causes brain damage. Traumatic brain injury usually results from a violent blow or jolt to the head or body. Symptoms include headache, dizziness, nausea or vomiting, mood changes, fatigue or drowsiness, difficulty sleeping, and memory or concentration problems. Risk factor includes age. Certain types of traumatic brain injury increase the risk of developing Alzheimer's disease and coordination problems. The traumatic brain injury drugs in development market research report provides an overview...
-
Product Insights
Dementia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Dementia is the loss of mental functions such as thinking, memory, and reasoning that is severe enough to interfere with a person's daily functioning. Symptoms include memory loss, hallucinations, agitation, personality changes, and difficulty with coordination and motor functions. Risk factors include age, smoking, obesity, high blood pressure, inflammation, and cardiovascular diseases. The Dementia Drugs in Development market research report provides an overview of the Dementia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dementia,...
-
Product Insights
Alzheimer’S Disease Disease – Global Clinical Trials Review, H2 2019
GlobalData's clinical trial report, “Alzheimer's Disease Global Clinical Trials Review, H2, 2019" provides an overview of Alzheimer's Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Alzheimer's DiseaseReport includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs...